ClinicalTrials.Veeva

Menu

A Retrospective Chart Review Study of Gene-Eden-VIR/Novirin

T

The Center for the Biology of Chronic Disease

Status

Completed

Conditions

Varicella-zoster Virus Infection
Herpes Simplex Infections
Epstein-Barr Virus Infections
Cytomegalovirus Infections
Human Papillomavirus

Treatments

Dietary Supplement: Gene-Eden-VIR/Novirin

Study type

Observational

Funder types

Other

Identifiers

Details and patient eligibility

About

This study measured the changes in health-related complaints by analyzing charts of individuals, who are infected with a latent virus, who have used Gene-Eden-VIR/Novirin.

Full description

The medical community calls the movement from severe to mild disease and from mild to normal health, 'relieving symptoms', and the interventions that cause such movement, drugs, medications, or therapies. The alternative community calls the movement from normal health to superior health, 'boosting health' (or boosting the immune system, or improving your sex drive, or boosting any another well functioning physiological system), and the interventions that cause such movement, natural remedies, dietary supplements, complementary treatments, etc. In general, these interventions aim to achieve superior performance of a normal human body. Of course, boosting the body's normal performance improves many of its capabilities, such as higher resistance to diseases, faster recovery from fatigue, better mental concentration, etc. Each movement presents different objectives. Relieving symptoms represents the ability of an intervention to reduce the frequency, duration, and severity of a disease. In contrast, boosting health represents the ability of an intervention to increase the frequency, duration, and quality of a person's health. In the current study, the investigators would like to measure the changes in health-related complaints by analyzing charts of individuals, who are infected with latent virus, and who have used Gene-Eden-VIR/Novirin.

Enrollment

1,000 patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Latent viral infection with either HSV, HPV, VZV, EBV, or CMV
  • Taking Gene-Eden-VIR/Novirin

Exclusion criteria

  • Use of other antiviral treatments

Trial design

1,000 participants in 5 patient groups

Herpes Simplex Virus Infection
Description:
Gene-Eden-VIR/Novirin, oral, 1-4 capsules per day, 12 months
Treatment:
Dietary Supplement: Gene-Eden-VIR/Novirin
Human Papillomavirus Infection
Description:
Gene-Eden-VIR/Novirin, oral, 1-4 capsules per day, 12 months
Treatment:
Dietary Supplement: Gene-Eden-VIR/Novirin
Epstein-Barr Virus Infection
Description:
Gene-Eden-VIR/Novirin, oral, 1-4 capsules per day, 12 months
Treatment:
Dietary Supplement: Gene-Eden-VIR/Novirin
Cytomegalovirus Infection
Description:
Gene-Eden-VIR/Novirin, oral, 1-4 capsules per day, 12 months
Treatment:
Dietary Supplement: Gene-Eden-VIR/Novirin
Varicella Zoster Virus Infection
Description:
Gene-Eden-VIR/Novirin, oral, 1-4 capsules per day, 12 months
Treatment:
Dietary Supplement: Gene-Eden-VIR/Novirin

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems